key: cord-0790860-so384fss
authors: GeurtsvanKessel, C. H.; Geers, D.; Schmitz, K. S.; Mykytyn, A. Z.; Lamers, M. M.; Bogers, S.; Gommers, L.; Sablerolles, R. S. G.; Nieuwkoop, N. N.; Rijsbergen, L. C.; van Dijk, L. L. A.; de Wilde, J.; Alblas, K.; Breugem, T. I.; Rijnders, B. J. A.; de Jager, H.; Weiskopf, D.; van der Kuy, P. H. M.; Sette, A.; Koopmans, M. P. G.; Grifoni, A.; Haagmans, B. L.; de Vries, R. D.
title: Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients
date: 2021-12-29
journal: nan
DOI: 10.1101/2021.12.27.21268416
sha: 459badb760bc59779ac74044668f717f5fa4b15f
doc_id: 790860
cord_uid: so384fss

The severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) Omicron variant (B.1.1.529) is spreading rapidly, even in vaccinated individuals, raising concerns about immune escape. Here, we studied neutralizing antibodies and T-cell responses to SARS-CoV-2 D614G (wildtype, WT), and the B.1.351 (Beta), B.1.617.2 (Delta), and B.1.1.529 (Omicron) variants of concern (VOC) in a cohort of 60 health care workers (HCW) after immunization with ChAdOx-1 S, Ad26.COV2.S, mRNA-1273 or BNT162b2. High binding antibody levels against WT SARS-CoV-2 spike (S) were detected 28 days after vaccination with both mRNA vaccines (mRNA-1273 or BNT162b2), which significantly decreased after 6 months. In contrast, antibody levels were lower after Ad26.COV2.S vaccination but did not wane. Neutralization assays with authentic virus showed consistent cross-neutralization of the Beta and Delta variants in study participants, but Omicron-specific responses were significantly lower or absent (up to a 34-fold decrease compared to D614G). Notably, BNT162b2 booster vaccination after either two mRNA-1273 immunizations or Ad26.COV.2 priming partially restored neutralization of the Omicron variant, but responses were still up to-17-fold decreased compared to D614G. CD4+ T-cell responses were detected up to 6 months after all vaccination regimens; S-specific T-cell responses were highest after mRNA-1273 vaccination. No significant differences were detected between D614G- and variant-specific T-cell responses, including Omicron, indicating minimal escape at the T-cell level. This study shows that vaccinated individuals retain T-cell immunity to the SARS-CoV-2 Omicron variant, potentially balancing the lack of neutralizing antibodies in preventing or limiting severe COVID-19. Booster vaccinations may be needed to further restore Omicron cross-neutralization by antibodies.

The severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) Omicron variant 58 (B.1.1.529) is characterized by a high number of mutations in the spike (S) protein that have immune 59 evasive potential. Based on transmission characteristics and immune evasion, the World Health 60 Organization (WHO) designated Omicron as a novel variant of concern (VOC). The Omicron variant has 61 been identified worldwide and models have predicted rapid surges of cases that could surpass earlier 62 peaks (1). More data are needed to understand the Omicron disease severity profile, and how severity 63 is impacted by vaccination and pre-existing immunity (2). 

However, vaccine efficacy differs and may be affected by waning of antibodies and the emergence of 90 variants (15, (26) (27) (28) . In general, boosting immune responses by additional vaccinations efficiently 91 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 4 restores antibody and T-cell responses, but clinical efficacy and protection against Omicron remains to 92 be determined.

We analysed humoral and cellular immune responses early and late (up to 6 months) after vaccination 95 with ChAdOx-1, S, Ad26.COV2.S, mRNA-1273 or BNT162b2 and performed in-depth analyses of cross-96 reactivity of neutralizing antibodies and T-cells against against the D614G (wildtype, WT), Beta, Delta 97 and Omicron variants. Additionally, we assessed cross-recognition of variants by neutralizing 98 antibodies and T-cells after booster vaccination. We found cross-neutralization of the Delta and Beta 99 variant in all vaccinated and convalescent individuals, but neutralization of Omicron was consistently 100 lower or even absent. Strikingly, all VOC were equally recognized by CD4+ T-cells. Booster vaccination 101 restored Omicron-specific neutralization, but still at significantly lower levels compared to D614G.

Cohort description

To assess binding antibody and T-cell responses after different vaccination regimens, we collected 107 serum and PBMC from N=400 participants, of which N=26 received two doses ChAdOx-1 S, N=75 108 received a single dose Ad26.COV2.S, N=199 received 2 doses of mRNA-1273, and N=100 received 2 109 doses of BNT162b2. Additionally, we measured responses in N=23 plasma donors with a confirmed 110 WT SARS-CoV-2 infection. Binding antibodies were assessed early (28 days after BNT162b2, mRNA-111 1273 or ChAdOx-1, or 56 days after Ad26.COV2.S) and late (6 months) after vaccination. T-cell 112 responses in whole-blood were assessed at 56 days and 6 months after vaccination (Ad26.COV2.S, 113 N=31), 28 days and 6 months after second vaccination (mRNA-1273, N=39), or exclusively at 6 months 114 after vaccination (ChAdOx-1 S, N=14). Virus neutralization and T-cell assays against VOC were 115 performed in a selection of N=15 participants from each vaccination group at the early and late 116 timepoint. The study design is shown in Figure 1A ; participant characteristics are summarized in Table   117 1.

Participants in the ChAdOx-1 S group were significantly older than participants in other groups 120 (p<0.0001, Kruskal-Wallis with multiple comparisons); other groups were comparable. Additionally, 121 the intervals between first and second vaccination were different for all groups that received two 122 vaccines: median interval for (1) ChAdOx-1 S was 56 days, (2) mRNA-1273 was 28 days, and (3)

BNT162b2 was 21 days (p<0.0001 for all comparisons, Kruskal-Wallis with multiple comparisons). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Vaccine-induced antibodies wane after 6 months, except in Ad26.COV2.S vaccinated HCW

Highest levels of S-specific binding antibodies were detected 28 days after full vaccination with mRNA-127 1273 or BNT162b2 (geometric mean titer [GMT] of 3985 and 3030 BAU/ml, respectively). A significant 128 reduction in GMT was observed after 6 months in both groups (Figure 1B, 

Human airway Calu-3 cells were used for virus propagation and neutralization assays because SARS-

CoV-2 enters these cells using the TMPRSS2-mediated entry pathway (29) (30) (31) (32) . This entry pathway is 147 used in vivo, and prevents adaptations in S, commonly observed in Vero cells. At 28 days post 148 vaccination, mRNA-1273 vaccination elicited highest PRNT50 against D614G and all variants, followed 149 by BNT162b2, ChAdOx-1 S, and Ad26.COV2.S vaccination. Delta and Beta variants were neutralized at 150 slightly lower PRNT50 (especially after vaccination with mRNA-based vaccines) and a significant 151 reduction of PRNT50 to Omicron was observed in all groups (p<0.0001 for ChAdOx-1 S, BNT162b2, and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 6 groups (p<0.0001, Friedman test with multiple comparisons). An 8-fold reduction in Omicron 161 neutralization was observed in the selection of 15 convalescent (after WT SARS-CoV-2 infection) sera 162 p=0.0004, Friedman test with multiple comparisons, Figure 2B ). Neutralizing antibodies to the D614G,

Beta and Delta variants correlated well to measured binding antibody levels, whereas a lower (but 164 significant) correlation was observed between Omicron-specific neutralizing antibodies and binding 165 antibody levels (Supplemental Figure 1 ).

Besides neutralizing antibodies, we assessed the presence of S-specific T-cell responses by activation- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Both boosting strategies led to rapid recall responses and a significant increase in binding antibody is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268416 doi: medRxiv preprint 8 further short-term boosting. Neutralizing antibodies are regarded the main correlate of protection 231 against infection with SARS CoV-2 (14, 15). The capacity of sera from vaccinated individuals to 232 neutralize the Omicron variant was reduced up to 30-fold, which is in line with another recent study 233 (37). To be protected against symptomatic COVID-19 caused by Omicron, affinity maturation will be 234 essential for the acquisition of broader neutralizing activity of RBD-binding antibodies that were is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

GeurtsvanKessel, SARS-CoV-2 variants of concern partially escape humoral but not T-cell 396 responses in COVID-19 convalescent donors and vaccinees. Sci Immunol 6, (2021).

. CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

. CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. 

. CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Corresponding authors: Corine H. GeurtsvanKessel (c.geurtsvankessel@erasmusmc.nl), Bart L. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

Samples from three different trials (HCW, ConCOVID, and SWITCH) were analysed in the scope of this 33 study (Supplemental Table 1 ). The HCW study was approved by the institutional review board of the 34 Erasmus MC (medical ethical committee, MEC-2020-0264) (1). The ConCOVID trial was also approved 35 by the institutional review board of the Erasmus MC (MEC 2020-0228). The study was registered at is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

CoV-2 variants of concern partially escape humoral but not T-cell 238 responses in COVID-19 convalescent donors and vaccinees

Effects of potent neutralizing 245 antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

Immunogenicity and reactogenicity of booster vaccinations after Ad26.COV.2.S priming

The RECOVAC Immune-Response Study The 257 immunogenicity, tolerability and safety of COVID-19 vaccination in patients with chronic 258 kidney disease, on dialysis, or living with a kidney transplant

SARS-CoV-2 productively infects human gut enterocytes

the first wave in 2020, all with a D614G SARS-CoV-2. In-depth neutralization and T-cell assays were 63 performed on a selection of N=15 participants from each group ( Table 1, Table 2 

The SARS-CoV-2-specific T cell response was measured by commercially available IFNɣ Release Assay 83 (IGRA, QuantiFERON, Qiagen) in whole blood as previously described and following the manufacturer's 84 description (4). In short, heparinized whole blood was incubated with three different SARS-CoV-2 85 antigens for 20-24h using a combination of peptides stimulating both CD4 + and CD8 + T-cells (Ag1, Ag2, 86 Ag3, QuantiFERON, QIAGEN). After incubation, plasma was obtained and IFNɣ production in response 87 to the antigens was measured by ELISA. Results are expressed in IU IFNɣ /ml after subtraction of the 88 NIL control values as interpolated from a standard calibration curve. Lower limit of detection in this 89 assay is set at 0.01 IU/ml, responder cut-off is 0.15 IU/m). IFNɣ production after stimulation with Ag2, 90 containing peptides covering the S protein, was shown in this study. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 4 1000 x g for 5 min and stored at −80°C in aliquots. Stock titers were determined by incubating 10-fold 98 dilutions of virus stock in OptiMEM at 37°C for 1 hour, after which they were transferred onto Calu-3 99 cells and incubated for 8 hours at 37°C in a humidified CO2 incubator. Next, cells were fixed with 4% 100 formalin, permeabilized in 70% ethanol, after which infected cells were stained with polyclonal rabbit 101 anti-SARS-CoV-2 nucleocapsid antibody (Sino Biological) and a secondary goat anti-rabbit IgG AF488 102 (Invitrogen). Stained plates were scanned on the Amersham Typhoon Biomolecular Imager (channel 103 Cy2; resolution 10 µm; GE Healthcare) and the number of infected cells was determined to calculate 104 the stock titer per milliliter. All work with infectious SARS-CoV-2 was performed in a Class II Biosafety 

No other minor variants >20% were detected. The delta (clade B.1.617.2) and omicron (clade 121 B.1.1.529) variant passage 3 sequences were identical to the original respiratory specimens and no 122 minor variants >20% were detected. Due to primer mismatches in the S1 region of the omicron spike 123 gene, amplicons 72, 73, 75 and 76 were sequenced at low coverage. Therefore, the S1 regions of the 124 original respiratory specimen and passage 3 virus were confirmed to be identical by Sanger sequencing.

The beta, delta and omicron sequences have been submitted to Genbank. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268416 doi: medRxiv preprint 6 (100 μg/ml; Lonza, Belgium), and 2 mM L-glutamine (Lonza, Belgium; R10H medium) and treated with 168 Benzonase (50 IU/ml; Merck) at 37°C for 30 min. Subsequently, 1 × 10 6 PBMCs were stimulated with is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 doi: medRxiv preprint 9 222 223 . CC-BY 4.0 International license It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021